NCT02046694View on ClinicalTrials.gov

A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 6, 2014

Primary Completion Date

April 6, 2020

Study Completion Date

April 6, 2020

Conditions
Acute Lymphoblastic Leukemia (ALL)
Interventions
DRUG

Allopurinol

At week 1, patients will begin allopurinol daily (100 mg for weight \>30 kg, 50 mg for weight ≤30 kg) and will restart 6-MP and methotrexate at 50 percent of the most recent dose. Patients will continue taking allopurinol in combination with 6-MP and methotrexate for the duration of the study (total of 8 weeks).

Trial Locations (3)

21287

Johns Hopkins Hospital, Baltimore

77030

Texas Children's Cancer and Hematology Centers, Houston

98105

Seattle Children's Hospital, Seattle

All Listed Sponsors
lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT02046694 - A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL | Biotech Hunter | Biotech Hunter